^
CANCER:

Vulvar Cancer

Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/15/2021
Initiation :
01/13/2017
Primary completion :
08/01/2022
Completion :
08/01/2022
CD4
|
PD-L1 overexpression • PD-L1 amplification
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • CMAB 819 (nivolumab biosimilar)
Phase 1/2
University of Florida
Recruiting
Last update posted :
10/14/2021
Initiation :
10/01/2021
Primary completion :
06/01/2023
Completion :
06/01/2024
TMB • CD4
|
Tecentriq (atezolizumab) • Fotivda (tivozanib)
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/05/2021
Initiation :
09/18/2017
Primary completion :
06/01/2022
Completion :
06/01/2022
PD-L1 • ALK
|
ALK positive • ALK negative
|
Opdivo (nivolumab) • Imlygic (talimogene laherparepvec) • CMAB 819 (nivolumab biosimilar)
Phase 1/2
National Cancer Institute (NCI)
Recruiting
Last update posted :
09/27/2021
Initiation :
01/27/2017
Primary completion :
01/01/2026
Completion :
01/01/2026
HLA-A
|
fludarabine IV • Proleukin (aldesleukin) • E7 TCR cells
Phase N/A
Wake Forest University Health Sciences
Recruiting
Last update posted :
09/27/2021
Initiation :
11/11/2019
Primary completion :
12/01/2021
Completion :
04/01/2022
HER-2
|
cisplatin • paclitaxel
Phase 1/2
National Cancer Institute (NCI)
Recruiting
Last update posted :
09/20/2021
Initiation :
08/11/2020
Primary completion :
10/01/2023
Completion :
10/01/2023
CD4
|
TILs
|
bintrafusp alfa (M7824) • PRGN-2009
Phase 1/2
National Cancer Institute (NCI)
Recruiting
Last update posted :
09/03/2021
Initiation :
06/09/2020
Primary completion :
01/30/2022
Completion :
01/01/2023
CD4
|
bintrafusp alfa (M7824) • M-9241 • PDS0101
Phase 1
Dana-Farber Cancer Institute
Recruiting
Last update posted :
08/31/2021
Initiation :
06/01/2018
Primary completion :
01/01/2022
Completion :
01/01/2022
PD-L1
|
Imfinzi (durvalumab) • tremelimumab (CP-675206)
Phase 2
Merck Sharp & Dohme Corp.
Recruiting
Last update posted :
08/26/2021
Initiation :
12/18/2015
Primary completion :
06/18/2026
Completion :
06/18/2026
TMB • MSI
|
TMB-H • MSI-H/dMMR
|
Keytruda (pembrolizumab)
Phase 1
Xencor, Inc.
Recruiting
Last update posted :
08/18/2021
Initiation :
05/29/2019
Primary completion :
06/01/2024
Completion :
11/01/2025
HER-2 • PD-L1 • ER • PGR
|
HER-2 negative
|
Keytruda (pembrolizumab) • pavunalimab (XmAb22841)
Phase 1/2
Tarveda Therapeutics
Recruiting
Last update posted :
07/14/2021
Initiation :
08/29/2017
Primary completion :
12/01/2021
Completion :
06/01/2022
HSP90AA1
|
5-fluorouracil • Zejula (niraparib) • irinotecan • leucovorin calcium • PEN-866
Phase N/A
Sorlandet Hospital HF
Recruiting
Last update posted :
07/08/2021
Initiation :
11/18/2019
Primary completion :
12/31/2024
Completion :
12/31/2030
TNFA • IL10 • IGFBP3
Phase 1
Xencor, Inc.
Recruiting
Last update posted :
04/29/2021
Initiation :
07/10/2018
Primary completion :
02/28/2022
Completion :
02/28/2023
HER-2 • ER • PGR • MSI
|
MSI-H/dMMR • HER-2 negative
|
vudalimab (XmAb717)
Phase 2
M.D. Anderson Cancer Center
Active, not recruiting
Last update posted :
02/24/2021
Initiation :
03/03/2017
Primary completion :
03/31/2021
Completion :
03/31/2021
CD4
|
Avastin (bevacizumab) • cisplatin • Tecentriq (atezolizumab) • Boyounuo (bevacizumab biosimilar) • HD204 (bevacizumab biosimilar) • HLX-04 (bevacizumab biosimilar) • MIL 60 (bevacizumab biosimilar)
Phase 2
M.D. Anderson Cancer Center
Recruiting
Last update posted :
12/02/2020
Initiation :
11/14/2018
Primary completion :
12/31/2021
Completion :
12/31/2022
CD4
|
Imfinzi (durvalumab) • rocakinogene sifuplasmid (INO-9012) • MEDI0457
Phase 2
National Cancer Institute (NCI)
Withdrawn
Last update posted :
10/03/2018
Initiation :
11/03/2017
Primary completion :
07/01/2021
Completion :
07/01/2021
PD-L1 • CD4
|
Opdivo (nivolumab) • Yervoy (ipilimumab)
Phase N/A
Northwestern University
Recruiting
Last update posted :
09/30/2016
Initiation :
03/01/2000
Primary completion :
12/01/2020
BRCA1 • BRCA2
Phase 1
Steven Waggoner, MD
Completed
Last update posted :
04/05/2013
Initiation :
02/01/2009
Primary completion :
04/01/2011
Completion :
04/01/2011
ABCB1
|
topotecan
Phase 1
National Cancer Institute (NCI)
Completed
Last update posted :
02/28/2013
Initiation :
08/01/1999
Primary completion :
02/01/2009
HER-2
|
HER-2 overexpression
|
Herceptin (trastuzumab) • carboplatin • Abraxane (albumin-bound paclitaxel)